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Available online 15 June 2013Abstract Neural stem/progenitor cells (NSC) respond to injury after brain injuries secreting IL-1, IL-6, TNF-α, IL-4 and IL-10,
as well as chemokine members of the CC and CXC ligand families. CXCL12 is one of the chemokines secreted at an injury site
and is known to attract NSC-derived neuroblasts, cells that express CXCL12 receptor, CXCR4. Activation of CXCR4 by CXCL12
depends on two domains located at the N-terminal of the chemokine. In the present work we aimed to investigate if the
N-terminal end of CXCL12, where CXCR4 binding and activation domains are located, was sufficient to induce NSC-derived
neuroblast chemotaxis. Our data show that a synthetic peptide analogous to the first 21 amino acids of the N-terminal end of
CXCL12, named PepC-C (KPVSLSYRCPCRFFESHIARA), is able to promote chemotaxis of neuroblasts in vivo, and stimulate
chemotaxis and proliferation of CXCR4+ cells in vitro, without affecting NSC fate. We also show that PepC-C upregulates
CXCL12 expression in vivo and in vitro. We suggest the N-terminal end of CXCL12 is responsible for a positive feedback loop to
maintain a gradient of CXCL12 that attracts neuroblasts from the subventricular zone into an injury site.
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914 T.R.M. Filippo et al.IntroductionCXCL12–CXCR4 axis plays important roles during CNS develop-
ment, controlling cerebellar neuronal progenitor cells (NPC)
migration (Ma et al., 1998; Zou et al., 1998), and increasing
cerebellar and cortical NPC proliferation (Klein et al., 2001;
Wu et al., 2009). In the mature brain, CXCL12 regulates neural
stem/progenitor cell (NSC) occupancy of the subventricular
zone (SVZ) vascular niche, and upregulates EGFR and integrin
α6 expression stimulating the exit and migration of NSC-
derived neuroblasts from the SVZ to the olfactory bulb
(Kokovay et al., 2010). Involvement of CXCL12 and CXCR4 in
brain pathologies has also been described. Migration of NSC
towards a brain tumor expressing CXCL12 is mediated by the
activation of CXCR4 (van der Meulen et al., 2009). Stroke and
traumatic injuries to the CNS lead to an inflammatory response
that includes local secretion of several chemokines that,
among other effects, attract NSC-derived neuroblasts from the
SVZ (Robin et al., 2006; Takeuchi et al., 2007; Itoh et al., 2009;
Galindo et al., 2011; Jaerve and Müller, 2012).
CXCL12 binds and activates two G-protein coupled recep-
tors, CXCR4 and CXCR7. Migration and proliferation of NSC and
NPC are regulated via activation of CXCR4, whereas the
activation of CXCR7 leads to cell survival (Bakondi et al.,
2011). To activate CXCR4, CXCL12 binding domain formed by
the amino acid residues 12–17 (RFFESH) binds to CXCR4 acting
as an initial docking site for CXCL12. Following binding, the
activation domain composed of amino acid residues 1–8
(KPVSLSYR) binds to the N-terminal end of the receptor,
inducing a conformational change that, in turn, allows binding
of G-protein to the intracellular domains of the receptor,
leading to activation of signaling pathways involved in the
control of migration, proliferation and survival (Crump et al.,
1997; Huang et al., 2003; Saini et al., 2011).
Due to CXCL12 pleiotropic effects there is increasing
interest to investigate this chemokine as a target for
therapeutic strategies to treat a number of brain pathologies.
CXCL12 pretreatment preserved dendritic spines of hippocam-
pus neurons submitted to neurotoxicity induced by amyloid-β
peptide oligomers in vivo (Raman et al., 2011). Increase in
CXCL12 expression by astrocytes after brain ischemia attracts
transplanted human umbilical cord cells expressing CXCR4 to
the injury site. Inhibition of CXCL12 activity by neutralizing
antibodies in vivo resulted in significant reduction in cord
blood cells at the injured area, reinforcing the view that
CXCL12–CXCR4 axis activates pathways that are keys for
homing of CXCR4 expressing cells (Rosenkranz et al., 2010).
The use of CXCL12 to increase chemotaxis and improve
survival of NSC to spinal cord and traumatic brain injuries
(SCI, TBI) is an approach that has been explored by several
groups, but there are still many molecular and cellular issues
to be addressed. Here, we provide evidence that a synthetic
peptide analogous to the N-terminal portion of CXCL12
containing the receptor binding and activating domains
enhances chemotaxis of neuroblasts from the SVZ to an
injured area in the cortex. Moreover, this effect seems to be
mediated by upregulation of CXCL12 locally, possibly by
astrocytes, as indicated by our in vitro experiments. The
synthetic peptide is also able to promote NSC proliferation in
vitro, without affecting differentiation. A modified peptide,
in which we substituted cysteines 9 and 11 by alanines, wasnot chemotactic for CXCR4 expressing cells but reduced
GFAP expression, suggesting that it could be useful to reduce
astrocyte reaction in vivo. The data we present here suggest
that the approach of using synthetic peptides that mimic
CXCL12 chemotactic effect is relevant for the development
of new therapeutic strategies to treat TBI and add infor-
mation regarding the role of CXCL12 N-terminal end on its
different biological activities.
Material and methods
Peptide synthesis
Peptides analogous to CXCL12 N-terminal were synthesized
by Fmoc (9-fluorenilmetoxicarbonil) technique (Hirata et
al., 1994) and characterized by HPLC (Shimadzu,Tokyo,
Japan) using a reverse phase Econosil C18 column (5 μm;
4.6 × 150 mm). The peptides were purified by semi prepar-
ative HPLC using a reverse phase Econosil C18 column (5 μm;
22.5 × 250 mm), and were analyzed by MALDI-TOF using a
TofSpec E Mass Spectrometer (Micromass, Manchester, UK).
The synthetic peptides were diluted in 0.1 M PBS pH 7.4 at a
final concentration of 3 M and maintained at −20 °C. The six
peptides synthetized and used in this study had the following
sequences:Pep1: KPVSLSYR-NH2
Pep2: KPVSLSYR-OH
Pep3: RFFESHIARA
Pep4: KPVSLSYR-epsilon-aminocaproic acid-RFFESHIARA
PepA-A: KPVSLSYRAPARFFESH
PepC-C: KPVSLSYRCPCRFFESHIARAMice
C57Bl/6 mice used in this study were maintained in ventilated
microisolator cages, under a cycle of light/dark (12 h/12 h),
with free access to water and food. All surgical interventions,
experimental protocols and handling of the animals followed
international guidelines (http://www.iclas.org/harmonization.
htm) and were approved by the Committee for Ethics in
Research of Universidade Federal de São Paulo (CEP 0096/09).
Isolation of adult NSC and neurosphere formation
Adult NSC were obtained from 6 weeks old C57Bl/6 mice SVZ.
Briefly, immediately after euthanasia, the brain was removed
from skull, the SVZwas dissected and cells were dissociated by
incubation with 125 mg/ml papain (Worthington Biomedical,
Lakewood, USA), during 5 min at 37 °C. After mechanical
dissociation, cells were strained through a sterile mesh
(0.4 μm) (BD Biosciences, Franklin Lakes, USA) and plated on
a 24-well plate at a density of 2 × 106 cells/well in PolyHema
(Sigma-Aldrich, St Louis, USA) precoated flasks. Cells were
cultured in DMEM high glucose:F12, 7:3 v/v (Gibco, San
Francisco, USA), containing 2% B27 (Invitrogen, Carlsbad,
USA), 20 ng/ml EGF (Sigma), 20 ng/ml FGF2 (R&D Systems,
Minneapolis, EUA), 1% penicillin/streptomycin (Gibco), and
5 μg/ml heparin (Sigma). Neurosphere formation takes up to
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changed every 4–5 days by centrifugation for 5 min at 358 ×g.
Half of the volume of the conditionedmediumwas replaced by
fresh medium.Isolation of cerebellar NPC
Cerebellar NPC were isolated from neonatal mouse cerebel-
lum as previously described (Klein et al., 2001; Zhou et al.,
2007). The cell suspension containing NPC was platted on
poly-L-lysine (Sigma) precoated plates at a density of
1 × 106 cells/35 mm dish or 3 × 105 cells/well on 24-well
plates. Cells were maintained in DMEM/F12 1:1, containing
20 mM KCl, 36 mM glucose and penicillin/streptomycin, at
37 °C, 5% CO2.Astrocyte primary culture
Astrocytes were obtained from the forebrains of neonatal
mice (P2). Briefly, mice were decapitated, the forebrains
were removed aseptically from the skulls and meninges were
excised carefully. After tissue mechanical dissociation, the
suspension was strained through a sterile mesh (0.4 μm) and
cells were seeded into culture flasks in DMEM low glucose,
containing 10% fetal bovine serum (FBS, Cultilab, Campinas,
Brazil), 1% glutamine 0.2 M and 1% penicillin/streptomycin.
Cells were incubated at 37 °C in a humidified atmosphere
containing 5% CO2. After 48 h in culture, the mixed glia was
vigorously shaked, and this resulted in detachment of
microglia, whereas astrocytes remained attached to the culture
flask. Culture medium was renewed every 3–4 days, and
astrocytes were characterized by GFAP immunocytochemistry.Chemotaxis assay
Lymphocytes
Chemotaxis of lymphocytes was measured using the Boyden
chamber assay. Adult human lymphocytes were obtained from
peripheral blood of healthy volunteers and separated by Ficoll–
Paque™ Plus (GE Healthcare, Piscataway, USA) gradient.
Lymphocytes (2 × 105 cells/250 μl/chamber) were placed on
the upper chamber, over a 5 mm pore membrane (Neuroprobe,
Pleasanton, USA). The six synthetic peptides were diluted in
RPMI (Invitrogen) and added to the bottom chamber at different
concentrations. Cells were allowed to migrate overnight, and
cells that went through the membrane were manually counted
using a Neubauer chamber.
NSC
Chemotaxis of adult NSC was measured using a custom
made Zigmond chamber (Zigmond and Hirsch, 1973). NSC
cultured as neurospheres were plated at the center of the
chamber and 3 × 10−8 M PepC-C was placed in one of the
slots and DMEM was placed on the other slot in order to
create a gradient surrounding the neurospheres. Cells were
allowed to migrate overnight at 37 °C in a CO2 incubator.
After the incubation period, cells were photographed using
an inverted microscope (Zeiss LSM510, Heidelberg, Germany)
and counted.TBImodel, injection of peptides and tissue preparation
Adult C57Bl/6 mice received four intraperitoneal (i.p.) in-
jections of BrdU (50 mg/kg body weight, in 0.1 M PBS pH 7.4),
in two consecutive days (2 injections/day). Twenty four hours
after the last injection, injury was performed as described
next. All surgeries were performed under anesthesia with i.p.
administration of ketamine chlorhydrate (66 mg/kg) (Dopalen
Vetbrands, Brazil). Injury to themotor cortexwas carried using
a previously described protocol (Chiba et al., 2004;
Coulson-Thomas et al., 2008) to produce a TBI. Briefly, a
metal needle was chilled by immersing it on isopentane on dry
ice and inserted four times intomicemotor cortex (stereotaxic
coordinates from bregma: AP +0.198 mm; LAT +0.175 mm; DV
−0.15 mm). Immediately after the lesion, while the animals
were still under anesthesia and using the same incision,
peptides or vehicle (PBS) were injected at the injury site.
Twenty four hours later, mice were anesthetized by an i.p.
injection of sodium thiopental (Tiopentax, Cristália, São
Paulo, Brazil) and euthanized. For qPCR experiments, the
brain was removed from the skull, the motor cortex was
dissected, and RNA was extracted by Trizol® (Invitrogen).
Alternatively, mice were intracardially perfused with 4%
paraformaldehyde (PFA) in 0.1 M PBS. The brain was removed
from the skull and immersed in 4% PFA for 24 h at 4 °C, placed
in 30% sucrose in PBS for 24 h at 4 °C, embedded in Tissue
Freezing Medium (Electron Microscopy Sciences, Hatfield, USA)
and frozen using isopentane on dry ice. The embedded tissue
was sliced into 12 μm coronal sections using a cryostat (Leica,
model CM 1900, Wetzlar, Germany). The tissue slices were
collected on silanized slides (Superfrost slides, Fisher Scientif-
ic, Philadelphia, USA) for immunofluorescence staining.
ELISA
Quantitation of CXCL12 in the supernatants of astrocyte
cultures was performed following 24 h of experimental treat-
ment. CXCL12 (PeproTech, São Paulo, Brazil) was added to the
cultures at a final concentration of 100 ng/ml. CXCL12 DuoSet
ELISA for mouse CXCL12 (R&D) was performed according to
manufacturer specifications. ELISAwas carried out in duplicates
of samples from two independent experiments. CXCR4 was
inhibited by AMD3465 (Tocris, Bristol, United Kingdom).
Quantitative real time PCR (qPCR)
Total RNA from dissected motor cortex or neurospheres was
extracted by Trizol® (Invitrogen) and quantified using
NanoDrop ND-1000 Spectrophotometer (NanoDrop Technol-
ogies, Wilmington, EUA). Two micrograms of total RNA was
reverse-transcribed with Oligo(dT)15 Primer and ImProm-II
Reverse Transcription System with Recombinant RNasin®
Ribonuclease inhibitor (Promega, Madison, USA) and MgCl2.
The primers used were: Cxcl12: sense 5′-ATC CTC AAC ACT
CCA AAC TGT GCC-3′; antisense 5′-TTC AGA CCT AGG CTC
CTC CTG TAA-3′; Cxcr4: sense 5′-AGC AGG TAG CAG TGA AAC
CTC TGA-3′; antisense 5′-TGG TGG GCA GGA AGATCC TAT
TGA-3′; Gfap: sense 5′-CTC AGT ACG AGG CAG TGG CC-3′;
antisense 5′-CGG GAA GCA ACG TCT GTG A-3′; Nestin: sense
5′-AGC AAC TGG CAC ACC TCA AG-3′; antisense 5′-GGT GTC
TGC AAG CGA AAG TTC-3′; Sox2: sense 5′-ATC CCA TCC AAA
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CT-3′; Cd133: sense 5′-TGG CAT TCT GTG TGG CTA TGT
TGC-3′; antisense 5′-TGC GAT AGT ACT TGG CCA GCT TG-3′;
Pax6: sense 5′-GAG GTC AGG CTT CGC TAA TG-3′; antisense
5′-GAG AGT TTT CTC CAC GGA CG-3′; Hprt: sense 5′-CTC ATG
GAC TGA TTA TGG ACA GGA C-3′; antisense 5′-GCA GGT CAG
CAA AGA ACT TAT AGC C-3′. qPCR was performed using SYBR
Green QPCR Master Mix (Agilent Technologies, Santa Clara,
USA) and Mx3005P Real-Time PCR System (Agilent Technol-
ogies). The thermal cycling conditions were 10 min at 95 °C,
and 40 cycles of 30 s at 95 °C, 1 min at 56 °C and 1 min at
72 °C. The relative expression levels of genes were calculated
using the 2−ΔΔCT method (Livak and Schmittgen, 2001).Preparation of neurosphere slices for BrdU staining
Whole neurospheres were taken from the flasks and fixed in 4%
PFA for 1 h at room temperature (r.t.). Neurospheres were
washed three times with PBS and then transferred to PBS/10%
sucrose solution for 2 h at r.t., PBS/20% sucrose solution for 2 h
at r.t. and, finally, PBS/30% sucrose solution at 4 °C overnight.
Neurospheres were then embedded in Tissue Freezing Medium
and frozen using isopentane on dry ice. Spheres were sliced at
10 μm on a cryostat and placed on silanized slides.Proliferation assays
[3H]-Thymidine incorporation
Cerebellar NPC proliferation was measured basically as
previously described (Porcionatto et al., 1998). Briefly, NPC
were obtained from P6 mice cerebella and were incubated in
the presence or absence of 10% FBS and peptides. [3H]-Thy-
midine (0.5 μCi/ml) was added and cells were incubated for
24 h. After the incubation period the amount of incorporat-
ed [3H]-thymidine was measured by liquid scintillation
counting.BrdU incorporation and detection
Adult NSC proliferation in vitro was measured by immuno-
cytochemistry and flow cytometry using Fluorescence Activated
Cell Analyser (Beckman Coulter, Fc500, Fullerton, USA) using
Cell Quest (The Cell Quest™ Software, Becton Dickinson
Immunocytometry Systems, San Jose, USA), after BrdU incor-
poration. Adult NSC were cultured as neurospheres and
maintained in the presence or absence of peptides during
4 days at 37 °C in a CO2 incubator. BrdU (0.2 μM) was added to
the medium in the last 24 h and, after this incubation period,
was analyzed either by immunofluorescence or by flow
cytometry. For flow cytometry, neurospheres were dissociated
with trypsin to yield a single cell suspension, and then were
fixed by 4% PFA in 0.1 M PBS, incubated in HCl 1.5 M for 30 min
at 37 °C, washed three times 10 min each in PBS and blocked in
5% FBS and 0.1% Triton X-100 (AMRESCO, Solon, USA) in PBS. For
immunofluorescence, the slices were incubated with anti-BrdU
(rat IgG, 1:300; Axyll/Accurate Chemical & Scientific Corpora-
tion, North Hempstead, USA) for 2 h and washed three times in
PBS. Cells were incubated with Alexa Fluor488-conjugated goat
anti-rat IgG, 1:300 (Molecular Probes, Carlsbad, USA) for 1 h
andwashed three times in PBS. DAPI solution (1:1000, Molecular
Probes) was used as a nuclear stain.Differentiation assay
Adult NSC were cultured as neurospheres and maintained
for 4 days in the presence or absence of pepA-A and
PepC-C. Expression of neural and stem cell markers was
assessed by flow cytometry using anti-GFAP (DAKO, Glostrup,
Denmark), anti-β-III tubulin (Sigma), anti-Nestin (Millipore,
Temecula, USA) and anti-NeuN (Millipore). Cells were incubated
with 1:300 dilutions of primary antibodies for 1 h. Cells were
washed with PBS, incubated with a 1:300 dilution of the
secondary antibodies (anti-rabbit Alexa 546-conjugated
[GFAP], anti-mouse Alexa 555-conjugated [β-III tubulin],
anti-mouse Alexa 350-conjugated [Nestin], anti-rat Alexa
488-conjugated [NeuN], Invitrogen). Ten-thousand events
were acquired per sample with fluorescence measured in
logarithmic scales using flow cytometer Fluorescence Activat-
ed Cell Analyser (Beckman Coulter) and Cell Quest (The Cell
Quest™ Software). Forward and side light-scatter gates were
used to exclude dead cells and debris. Data were gated using
side scatter (linear scale) and fluorescence signals (logarith-
mic scale). Negative controls were carried out in the absence
of primary or secondary antibodies. Three experiments were
carried out in duplicates.Immunofluorescence
Fixed coronal brain sections or the neurospheres were
exposed to 0.1% Triton X-100 for 10 min, washed in PBS
three times, blocked with 5% FBS for 1 h at r.t. and then
incubated overnight at 4 °C with the primary antibodies
rabbit anti-GFAP, mouse anti-Nestin, mouse anti- anti-β-III
tubulin, mouse anti-NeuN and rat anti-BrdU with 1:300
dilutions. The motor cortex sections or the neurospheres
were then washed in PBS and incubated with appropriate
secondary antibodies (Alexa Fluor546-conjugated [GFAP],
goat anti-mouse IgG 1:300, AlexaFluor488-conjugated
[NeuN] goat anti-rabbit 1:300, Alexa Fluor488 [BrdU]
anti-rat IgG, 1:300, and anti-mouse Alexa 555-conjugated
[β-III tubulin] Invitrogen). Nuclei were stained with DAPI
(1:1000). After immuno- and DAPI staining, glass slides were
mounted using Fluoromount G (Electron Microscopy Sci-
ences, Hatfield, USA). The fluorescently labeled cells were
analyzed using a Zeiss LSM510 scanning confocal inverted
microscope (Zeiss, Oberkochen, Baden-Wurttemberg, Ger-
many) and co-localization images were generated using
Zeiss LSM Image Browser. In order to quantify BrdU + cells
at the injury site, two consecutive sections of motor cortex
stained for GFAP (green) and BrdU (red) were photographed
and photos were transferred to Adobe Photoshop®. The
total number of BrdU + cells was counted blind and the
result is the average of three animals.Statistical analysis
Statistically significant differences were evaluated by
one-way ANOVA followed by Tukey post-test using the
GraphPad Prism software version 5.01 (GraphPad Software,
USA). Results are expressed as mean ± SEM and were consid-
ered significant if p b 0.05.
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migration of CXCR4 expressing cells
We synthesized six peptides analogous to CXCL12 N-
terminal end to use in this study. Two of these peptides were
composed of the first 8 amino acids of CXCL12, mimicking the
region that contains the receptor activation domain (Pep1:
KPVSLSYR-NH2; Pep2: KPVSLSYR-OH); one peptide had the
sequence of 12–21 amino acids, that corresponds to the
receptor binding domain (Pep3: RFFESHIARA); and three
peptides carried both, the receptor binding and receptor
activating domains. The difference among these three
peptides was that one of them had the exact structure of the
first 21 amino acids of the native CXCL12 N-terminal end
(PepC-C: KPVSLSYRCPCRFFESHIARA); the second had the two
cysteines that are critical for CXC chemokine activity (C9 and
C11) substituted by alanines (PepA-A: KPVSLSYRAPARFFESH),
and the third had the CXC tripeptide substituted by
ε-aminocaproic acid, that functions as a linker to separate
the binding and activation domains (Pep4: KPVSLSYR-ε-
aminocaproic acid-RFFESHIARA). Chemotactic activity of the
peptides was first tested using lymphocytes, cells that express
CXCR4. The use of blind end chambers (Boyden chamber)
to test chemotaxis of lymphocytes towards a source of
chemokines, such as CXCL12, has been extensively described
in the literature. In this assay, concentrations of CXCL12
varying from 0.5 to 1.0 × 10−7 M are able to promote
lymphocyte migration (Pelletier et al., 2000). The ability of
each synthetic peptide to promote chemotaxis of lymphocytes
in a Boyden chamber assay was tested in concentrations
varying from 1.0 × 10−8 M to 1.0 × 10−4 M. Among the six
peptides, PepC-C showed the highest activity, stimulating the
migration of around 70% of the lymphocytes added to the
upper chamber at a concentration of 3.0 × 10−8 M (Fig. 1A).
Peptides with activation and binding domains only, Pep3 and
Pep1, respectively, showed lower chemotactic activity (~30–
40% of cells migrated) even when used at concentration 10
times higher than the effective concentration found for
PepC-C. Substitution of C9 and C11 by alanines abolished the
chemotactic activity of the peptide, and PepA-A only showed
some chemotactic activity (~20% of cells migrated) when used
at a concentration 100 times higher than the concentration
found to be effective for PepC-C. From the six peptides
tested, only Pep4 did not promote chemotaxis of lymphocytes
even at a concentration 1000 times higher than the effective
concentration encountered for PepC-C (Fig. 1A).
Based on the lymphocyte chemotaxis assay, PepC-C was
selected to test the ability of CXCL12 N-terminal to promote
migration, proliferation and differentiation of adult SVZ
NSC-derived neuroblasts. PepA-A was selected to be used as
control peptide because it presented low chemotaxis
activity and differed from PepC-C by only two aminoacids
(C9A and C11A). Before looking at proliferation and
expression of cell differentiation markers we tested the
peptides as promoters of NSC migration. NSC from the
SVZ form floating neurospheres in culture and, if allowed to
adhere to laminin, NSC-derived cells (glia and neuroblasts)
migrate out of the sphere, recapitulating the exit of
type A cells (neuroblasts) from the neurogenic niche(Alvarez-Buylla & Lim, 2004). PepC-C and PepA-A were
used in concentrations which stimulated the highest
percentage of lymphocyte migration, PepC-C was used at
3 × 10−8 M and PepA-A at 3 × 10−6 M, respectively. Only
PepC-C was able to increase migration of cells out of the
neurospheres when added uniformly to the culture medium
(Fig. 1B). A gradient of PepC-C also promoted migration of
cells out of the neurospheres on a Zigmond chamber assay,
demonstrating that the peptide not only stimulates random
migration but also has chemotactic activity (Fig. 1B). When
submitted to a uniform concentration of peptides, cells
migrated longer distances from the neurosphere when com-
pared to untreated cells, similar to what we had observed for
cells treated with CXCL12 (Fig. 1C). In addition, the percentage
of neurospheres that had cells migrating more than 150 μmwas
higher when cells were treated either with CXCL12 or PepC-C
when compared to cells treated with PepA-A or not treated
(Fig. 1D).CXCL12 N-terminal peptide induces chemotaxis of
neuroblasts in vivo
As the synthetic peptideswere able to stimulatemigration and
chemotaxis of cells in vitro, we asked if this activity could also
be observed in vivo. Using an animal model for TBI, we
evaluated the exit of neuroblasts from the SVZ 24 h after an
injury was produced in the motor cortex of mice. Neuroblasts
are constantly generated by NSC in the SVZ neurogenic niche,
so they can be labeled with BrdU and traced afterwards. As
expected, in non-injured brains we observed BrdU + cells
lining the lateral ventricle wall (Fig. 2A), and when the injury
was produced in the motor cortex, BrdU + cells could be seen
leaving the SVZ (Fig. 2B). Injection of PepC-C, but not PepA-A,
at the injury site immediately after injury, greatly increased
the amount of BrdU + cells in the migratory stream
(Figs. 2A-D). Quantification of BrdU + cells at the injury site
revealed that PepC-C more than doubled the number of cells
that arrived at the injury site in 24 h when compared to
untreated animals, treated with vehicle or treated with
PepA-A (Fig. 3).
Althoughwe did not measure the peptides half-life in vivo, it
is expected that they would be short living. It is likely that the
peptides probably last only a few minutes after being injected
in situ due to the presence of several proteases at the injury
site. To explain how a single injection of peptidewould enhance
attraction of neuroblasts to the injury site we looked at the
expression of CXCL12 locally and observed that PepC-C, but not
PepA-A, was able to triple the levels of Cxcl12 mRNA locally,
after 24 h (Fig. 4A), without interfering with the expression of
Cxcr4 (Fig. 4B).
Astrocytes respond to injury signals secreting CXCL12,
among other soluble factors and molecules associated with
the extracellularmatrix. In order to investigatewhether PepC-C
was able to stimulate CXCL12 expression and secretion by
astrocytes we treated cultures of mice astrocytes with PepC-C
and PepA-A, and measured the concentration of CXCL12 in the
culture medium. PepC-C and PepA-A, alone or combined, did
not increase the release of CXCL12 to the culture medium
(Fig. 4C). Next, we asked if PepC-C could stimulate a positive
feedback loop of CXCL12 secretion. To investigate this, CXCL12
was added to the astrocytes in culture tomimic CXCL12 present
Figure 1 Synthetic peptides analogous to CXCL12 N-terminal are chemotactic for CXCR4 expressing cells. (A) Lymphocyte
chemotaxis in response to the concentration of the synthetic peptide that showed highest stimulation. The number of lymphocytes
that migrated in the Boyden chamber assay was calculated by counting cells that migrated to the bottom in 24 h in relation to the
initial number of cells placed on the upper chamber (initial input 2 × 105 cells). (B) NSC migration and chemotaxis assays were
performed by adding CXCL12, peptides PepA-A and PepC-C to neurosphere culture medium (Uniform), or performed in a Zigmond
chamber (Gradient). The distance traveled by migrating cells from the neurospheres is highlighted by the white lines. For Zigmond
chamber assay, PepC-C was added to one slot of the chamber and culture medium was added to the other slot. Neurospheres were
placed between the two slots and cells that migrated towards each slot were counted. (C) Distance traveled by NSC was calculated by
measuring the distance from the border of the neurospheres to the border of the migration radius (white lines in panel B), using
ImageJ. CXCL12, PepA-A and PepC-C treatments were compared to “no peptide” (* p b 0.05). (D) Percentage of neurospheres that
had cells migrating 150 μm from the neurospheres border or more, after 18 h of treatment (* p b 0.05). Number of neurospheres
analysed for each treatment condition: no peptide, 29; CXCL12, 30; PepA-A, 31; and PepC-C, 29.
918 T.R.M. Filippo et al.at the injury site in vivo. CXCL12 secreted to the medium
was measured, and we observed that the addition of PepC-C
increased CXCL12 concentration by three fold, whereas PepA-A
did not (Fig. 4C). Inhibition of CXCL12 receptor (CXCR4) did not
interfere with the increase in CXCL12 secretion stimulated by
Pep-C-C, indicating that CXCL12 production and secretion is
independent of CXCR4 activation.PepA-A represses expression of Gfap at the injury
site
As part of the glial reaction, injury to the brain causes
upregulation of Gfap and Nestin. In the model used in this
study we observed increased expression of Gfap and Nestin
Figure 2 PepC-C stimulates neuroblast migration in vivo. Sections of motor cortex showing BrdU + neuroblasts (red) and
GFAP + astrocytes (green). (A) Control, not injured; (B) injured, vehicle injected; (C) injured, PepA-A injected; (D) injured, PepC-C
injected. To prelabel neuroblasts, mice received four i.p. injections of BrdU, in two consecutive days (two injections/day); 24 h after
the last BrdU injection, injury was performed. Peptide injections were made at the injury site immediately after injury. Animals were
euthanized 24 h after injury. Arrows indicate BrdU + neuroblasts, and the injury site is in the upper part of each photo. PepC-C
increased the number of cells that left LV towards injury site 24 h after injury. LV: lateral ventricle.
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regulated the expression of both genes to levels similar to
control (non injured brain). In contrast, PepC-C had no
effect on the expression of Gfap and Nestin, but upregulated
the expression of the proliferation marker Sox2, which was
unaffected by injury or by treatment with PepA-A (Fig. 5A).
PepA-A also downregulated the expression of Gfap by NSC
in vitro without affecting Nestin and Sox2 expression
(Fig. 5B). Similar to what we had observed in vivo, PepC-C
did not change Gfap expression by NSC when compared to
control untreated cultures, and upregulated Sox2. Nestin
expression in vitro was upregulated by PepC-C and was not
affected by treatment with PepA-A (Fig. 5B).CXCL12 N-terminal is sufficient to induce neural
stem cell proliferation but does not change NSC fate
Because PepC-C upregulated the expression of Sox2 both in
vitro and in vivo, we decided to evaluate its effect on
neuronal precursor proliferation. Neurospheres treated with
CXCL12 or PepC-C showed increased mRNA expression of the
stem cell marker Cd133, when compared to non-treated or
PepA-A treated cultures (Fig. 6A). Using cerebellar NPC,
cells that express CXCR4, we observed increased prolifera-
tion when cells were treated with PepC-C, even in the
absence of FBS, whereas PepA-A did not show any prolifer-
ative activity (Fig. 6B).NSC cultured in the presence of PepC-C showed increased
proliferation assessed by BrdU incorporation and analyzed by
immunocytochemistry and flow cytometry (Figs. 6C–D).
TUNEL assay revealed that the peptides did not interfere
with the apoptosis of NSC in vitro (Fig. 6E).
Following the observation that the peptides were able to
stimulate migration, chemotaxis and proliferation of NSC, as
well as to modify gene expression, we then evaluated if they
could affect NSC fate.We first looked at the expression of Pax6,
a transcription factor known to be critical for differentiation of
neural precursors into neurons. The results show that PepA-A
downregulated Pax6 in NSC when compared to untreated cells
(Fig. 6 F). Cytometry analysis showed that the percentage of
GFAP+,β-III tubulin+, Nestin + and NeuN + cells did not change
with treatment with PepC-C or PepA-A (Fig. 6 F).Discussion
In this study we provide evidence that the N-terminal end of
CXCL12, a region containing CXCR4 binding and activation
domains, is sufficient to induce both migration and prolifer-
ation of SVZ-born neuroblasts. Our experimental approach
was to synthesize peptides that are analogous to CXCL12
N-terminal, introducing modifications such as replacement of
the tripeptide C9-P10-C11 by a linker that separates the
receptor binding and receptor activation domains or replacing
C9 and C11 by A (PepA-A). As predicted, the synthetic peptides
Figure 3 PepC-C increased the number of neuroblasts that migrated from the SVZ and arrived at the injury site. (A) Sections of
motor cortex injury site, showing BrdU + neuroblasts (red) and GFAP + astrocytes (green). (B) Quantification of BrdU + cells at the
injury site 24 h after injury. PepC-C increased the number of cells that arrived at the injury site when compared to injury not treated,
treated with vehicle or treated with PepA-A (* p b 0.05).
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Figure 4 PepC-C stimulates expression of Cxcl12 in vivo and in vitro. RNA was extracted from primary motor cortex of mice and
qPCR was used to quantify the expression of Cxcl12 (A) Cxcr4 (B). Results presented are average of mRNA from 3 animals, qPCR was
performed in triplicates and values are expressed as mean ± SEM, and are relative to the expression of Hprt. After 24 h, PepC-C
upregulated Cxcl12 expression locally, without interfering with Cxcr4 expression (* p b 0.05 when the treated group was compared to
“No injury”; # p b 0.05 when the treated group was compared to “Injury”). (C) Astrocytes were cultured in the presence (+) or
absence (−) of CXCL12 (100 ng/ml), PepA-A, PepC-C and CXCR4 inhibitor (AMD3465). The total amount of CXCL12 released from
astrocytes during 24 h was measured by ELISA. PepC-C plus CXCL12 increased the amount of CXCL12 in the medium, and this response
was not inhibited by AMD3465 (* p b 0.05 comparison of each treatment with no treatment; # p b 0.05).
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domain (Pep1 and Pep2) showed little chemotactic activity,
and were less active when compared to the complete CXCL12
molecule or to the peptide that had both domains (PepC-C).
Similar results were obtained by Crump et al. (1997), using
chimeras containing CXCL12 N-terminal end (receptor activa-
tion domain) and the REFFESH sequence (receptor binding
domain) and showed that they were chemotactic for lympho-
cytes, demonstrating the chimeras contained the contact
residues essential for functional CXCL12. Here, we not only
corroborate those findings but in addition demonstrate that
the alanine-modified peptide (PepA-A) was less chemotactic
than CXCL12 and PepC-C and had no proliferative activity
on CXCR4+ NSC or cerebellar NPC in vitro. Once we
determined that PepC-C was as good chemotactic factor as
CXCL12 in vitro we evaluated its ability to promote chemo-
taxis in vivo.
It has been extensively described that after an injury to the
brain or spinal cord the expression of CXCL12, among otherchemokines and cytokines that are part of the inflammatory
response, rises at the injury site. Following ischemic stroke,
SCI or TBI, the blood–brain barrier becomes dysfunctional or
disrupted, allowing circulating immune cells to infiltrate,
interact with and activate resident immune cells. Activated
glial cells (astrocytes, microglia and oligodendrocytes) start
expressing chemokines such as CCL2, CCL3, CXCL1, CXCL2 and
CXCL12, as part of the local inflammatory response (Kim et
al., 1995; Takami et al., 1997; Hill et al., 2004; Pineau et al.,
2010; Galindo et al., 2011). The current knowledge about the
dynamics of chemokine expression in CNS injury and repair has
been recently reviewed by Jaerve and Müller (2012).
Using a TBI mouse model we show here that PepC-C, but
not PepA-A, is able to promote migration of NSC from the SVZ
towards the injury site. Twenty four hours after injury it was
possible to observe that the number of BrdU prelabeled cells
arriving at the traumatic injury and peptide administration
site doubled when compared to animals subjected to injury
but not treated or treated with vehicle or A-substituted
Figure 5 CXCL12 N-terminal peptides alter injury-related gene expression. Relative expression of Gfap, Nestin, Sox2 in motor
cortex (A) and by neurospheres (B) in response to treatment with PepA-A, PepC-C and CXCL12. Results presented are average of mRNA
from 3 animals (motor cortex) or 3 independent experiments (neurospheres); qPCR was performed in triplicates and values are
expressed as mean ± SEM (* p b 0.05 when each treatment group was compared to “No injury” or “No peptide”; # p b 0.05 when each
treatment group was compared to “Injury” or “CXCL12”).
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measure the peptide half-lives at the site of injury and
injection, but there is data suggesting that the peptides would
not last long. For example, a tripeptide analogous to the
N-terminal of insulin-like growth factor I (IGF-I) lasted only 3 h
following intracerebroventricular administration in the pres-
ence of peptidase inhibitors (Baker et al., 2005). Based on that
and on the fact that several proteases are secreted after
injury to the CNS (Agrawal et al., 2008), we considered that
the peptides would not last for 24 h of in vivo experiment. To
find a possible mechanism for the prolonged duration of
chemotactic activity of PepC-C in vivo, we hypothesized that a
gradient of CXCL12 could be formed if PepC-C stimulated the
release of high amounts of CXCL12 at the injury site thatwould
diffuse away from the source, reaching the SVZ cells. To verify
that, we looked at Cxcl12 mRNA at the injury site 24 h after
injury and peptide administration and observed that PepC-C,
but not PepA-A, doubled the local levels of Cxcl12 mRNA.
There is no information regarding the modulation of CXCL12
expression by astrocytes after TBI, but based on data that
shows upregulation of CXCL12 expression by astrocytes in
response to ischemia (Hill et al., 2004; Miller et al., 2005), weinvestigated if those cells were the ones responsible for the
increase in Cxcl12 mRNA we observed in vivo. To do that, we
exposed astrocytes in culture to the peptides and measured
CXCL12 protein by ELISA. Surprisingly, PepC-C alone was not
able to induce the release of CXCL12 to the culture medium,
but acted synergistically with CXCL12, increasing the concen-
tration of CXCL12 in the culture medium after 24 h. It is well
documented that CXCL12 is internalized upon binding to
CXCR4 (Amara et al., 1997; Signoret et al., 1997; Haribabu et
al., 1997). When astrocytes were treated with CXCL12 alone
the concentration of the chemokine in the culture medium
after 24 h was ~10 ng/ml, that represents ~10% of the
original input (100 ng/ml), so the increase from ~10 ng/ml
to ~30 ng/ml when cells were exposed to CXCL12 + PepC-C
could be explained by inhibition of CXCR4 internalization. To
verify this we treated the astrocytes in the presence of a
specific CXCR4 inhibitor (AMD3465) (Hatse et al., 2002) and
did not observe any difference in the concentration of CXCL12
in the presence of peptides and/or CXCL12 and absence of
AMD3465, indicating that PepC-C stimulated expression and
secretion of CXCL12 rather than inhibited its internalization
via CXCR4 activation. Two aspects are very interesting about
Figure 6 CXCL12 N-terminal is sufficient to increase proliferation of NSC but does not affect differentiation. (A) PepC-C
upregulated the expression of the stem cell marker Cd133 by NSC cultured as neurospheres. (B) Proliferation of cerebellar NPC was
assessed by [3H]-thymidine incorporation in the presence or absence of peptides and 10% FBS. Proliferation of NSC was measured by
BrdU incorporation using immunohistochemistry (C) and flow cytometry (D). (E) Arrows indicate nuclei labeled by TUNEL assay. (F)
PepA-A downregulated the expression of Pax6 by NSC cultured as neurospheres. PepA-A and PepC-C did not alter differentiation of
NSC, measured by GFAP, β-III tubulin, Nestin and NeuN using flow cytometry. qPCR was performed in triplicates and values are
expressed as mean ± SEM. Results presented are average of 3 independent experiments. [3H]-Thymidine incorporation results
presented are the average of 3 independent experiments, each performed in duplicates (#p b 0.05 compared to "no serum/no
peptide"; *p b 0.05 compared to "+10%FBS/no peptide").
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expression, it requires CXCL12 to be effective; and second, it
does not involve CXCR4 signaling. Our suggestion is that this
stimulatory effect could be elicited by the activation ofCXCR7, a recently described G-protein coupled receptor for
CXCL12 (Burns et al., 2006; Schönemeier et al., 2008; Odemis
et al., 2010). The molecular mechanisms involved in
PepC-C-induced CXCL12 expression/secretion by astrocytes
924 T.R.M. Filippo et al.were not the focus of the present work and deserve further
investigation.
Once we determined that PepC-C upregulated CXCL12
expression at the injury site and enhanced chemotaxis of NSC
from the SVZ, we further investigated if the peptides would
modulate the expression of markers for peri-injury reactive
astrocytes Gfap, Nestin and Sox2 (Nakagomi et al., 2009;
Shimada et al., 2010, 2012). Similar to what is observed for
ischemia, Gfap and Nestin were upregulated by the traumatic
injury, whereas Sox2 expression did not change. The expression
of Gfap and Nestin after injury was not affected by the
administration of PepC-C, but the expression of Sox2 was
greatly increased by this treatment, suggesting that PepC-C
could be increasing proliferation of astrocytes at the injury site.
Upregulation of Sox2 was also observed in vitro, when adult
NSC cultured as neurospheres were exposed to PepC-C, and we
confirmed PepC-C proliferative effect on NSC and cerebellar
NPC, in vitro, by [3H]-thymidine and BrdU incorporation.
One unexpected set of data we got was the downregulation
of Gfap by the modified peptide PepA-A both in vivo and
in vitro. PepA-A has low chemotactic activity in vitro, no
chemotactic activity in vivo, does not increase CXCL12 ex-
pression by astrocytes and does not have proliferative effect on
NSC or cerebellar NPC in vitro. Besides downregulating ex-
pression of Gfap, the substitutions C9A and C11A led to
downregulation of Pax6, a transcription factor involved in NSC
fate determination. Pax6 induces neurogenic fate in SVZ glial
progenitors by repressing Olig2 expression (Jang and Goldman,
2011) and the loss of Pax6 enhances astrogenesis (Sugimori
et al., 2007; Sakayori et al., 2012). In conclusion, we show
here that the N-terminal of CXCL12, a region containing the
receptor binding and activation domains, is sufficient to
stimulate proliferation and chemotaxis of NSC from the adult
SVZ to an injury site in the cortex. These actions are likely
performed via activation of the G-protein coupled receptor
CXCR4, but we do not rule out the participation of CXCR7
in signaling a proposed positive feedback loop for CXCL12
expression and secretion.
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